2SEVENTY BIO INC (TSVT) Forecast, Price Target & Analyst Ratings
NASDAQ:TSVT • US9013841070
5 USD
+0.01 (+0.2%)
At close: May 12, 2025
5 USD
0 (0%)
After Hours: 5/12/2025, 8:00:01 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for 2SEVENTY BIO INC (TSVT).
Forecast Snapshot
Consensus Price Target
$5.10
+ 2.00% Upside
Next Earnings Forecast
Release DateAug 5, 2025
PeriodQ2 / 2025
EPS Estimate-$0.15
Revenue Estimate13.701M
ChartMill Buy Consensus
47.50%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.10
Upside
+ 2.00%
From current price of $5.00 to mean target of $5.10, Based on 8 analyst forecasts
Low
$5.05
Median
$5.10
High
$5.25
Price Target Revisions
1 Month
0.00%
3 Months
-23.08%
Price Target Summary
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5.
The average price target has been revised downward by 23.08% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
47.50%
TSVT was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about TSVT.
In the previous month the buy percentage consensus was at a similar level.
TSVT was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-07-29 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-06-27 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-05-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-04-08 | Citigroup | Maintains | Buy -> Buy |
| 2024-03-18 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-01-31 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-01-31 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-20 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-10-30 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2023-10-12 | Citigroup | Initiate | Buy |
| 2023-09-13 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-09-13 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2023-09-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-15 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-07-28 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-28 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2023-07-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-05-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-15 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-03-17 | Wedbush | Maintains | Outperform |
| 2023-01-24 | Morgan Stanley | Maintains | Overweight |
| 2023-01-20 | Goldman Sachs | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 5, 2025
PeriodQ2 / 2025
EPS Estimate-$0.15
Revenue Estimate13.701M
Revenue Q2Q52.79%
EPS Q2Q-134.00%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
5.40%
EPS (1 Month)
0.00%
EPS (3 Months)
-15.65%
Next Earnings Summary
TSVT is expected to report earnings on 8/5/2025. The consensus EPS estimate for the next earnings is -0.15 USD and the consensus revenue estimate is 13.70M USD.
The next earnings revenue estimate has been revised upward by 5.4% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 91.5M 67.89% | 100.387M 9.71% | 37.862M -62.28% | 69.849M 84.48% | 76.618M 9.69% | 80.932M 5.63% | 85.797M 6.01% | 89.449M 4.26% | 111.4M 24.54% | 102.62M -7.88% | 109.26M 6.47% | |
| EBITDA YoY % growth | -241.97M 15.82% | -206.653M 14.60% | -91.478M 55.73% | -42.541M 53.50% | -6.456M 84.82% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -253.5M 16.56% | -216.938M 14.42% | -98.574M 54.56% | -32.64M 66.89% | -12.497M 61.71% | 128.01K 101.02% | -6.936M -5,518.33% | 4.998M 172.06% | 22.848M 357.14% | N/A | N/A | |
| Operating Margin | -277.05% | -216.10% | -260.35% | -46.73% | -16.31% | 0.16% | -8.08% | 5.59% | 20.51% | N/A | N/A | |
| EPS YoY % growth | -7.58 44.11% | -4.02 46.99% | -1.12 72.14% | -0.47 58.41% | -0.24 48.91% | 0.28 215.72% | 0.42 51.85% | 0.61 46.34% | 0.91 48.33% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.17 82.83% | -0.15 -134.00% | -0.08 58.88% | -0.02 93.57% |
| Revenue Q2Q % growth | 14.242M 84.29% | 13.701M 52.79% | 15.911M 17.56% | 18.054M 517.02% |
| EBITDA Q2Q % growth | -13.475M 69.08% | -9.618M 39.47% | -6.239M 21.98% | N/A |
| EBIT Q2Q % growth | -14.388M 68.51% | -12.14M 38.28% | -7.897M 41.24% | -4.794M 75.75% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
30.96%
EPS Next 5 Year
20.56%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
18.14%
Revenue Next 5 Year
12.75%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
2SEVENTY BIO INC / TSVT Forecast FAQ
What is the average price target for 2SEVENTY BIO INC (TSVT) stock?
8 analysts have analysed TSVT and the average price target is 5.1 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 5.
What is the next earnings date for TSVT stock?
2SEVENTY BIO INC (TSVT) will report earnings on 2025-08-05, before the market open.
What are the consensus estimates for 2SEVENTY BIO INC (TSVT) next earnings?
The consensus EPS estimate for the next earnings of 2SEVENTY BIO INC (TSVT) is -0.15 USD and the consensus revenue estimate is 13.70M USD.
Can you provide the expected long term growth rate for 2SEVENTY BIO INC stock?
The expected long term growth rate for 2SEVENTY BIO INC (TSVT) is 18.14%.